Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Application
Filed:
December 28, 2012
Publication date:
April 25, 2013
Applicants:
NSABP FOUNDATION, INC., GENOMIC HEALTH, INC.
Inventors:
GENOMIC HEALTH, INC., NSABP FOUNDATION, INC.
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
March 6, 2012
Date of Patent:
February 5, 2013
Assignees:
Genomic Health Inc., NSABP Foundation, Inc.
Inventors:
Wayne Cowens, Joffre B. Baker, Kim Clark-Langane, James Hackett, Drew Watson, Soonmyung Paik
Abstract: The invention relates to methods of using fragmented RNA, such as RNA obtained from archived fixed paraffin-embedded tissue material (FPET RNA) or other clinically biopsied tissue specimens for universal gene expression profiling.
Abstract: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
Type:
Application
Filed:
July 5, 2012
Publication date:
October 25, 2012
Applicants:
BRISTOL-MYERS SQUIBB COMPANY, GENOMIC HEALTH, INC.
Inventors:
Joffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford
Abstract: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
Type:
Grant
Filed:
May 13, 2009
Date of Patent:
September 25, 2012
Assignees:
Genomic Health, Inc., Bristol-Myers Squibb Company
Inventors:
Joffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
September 25, 2012
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
June 12, 2012
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
April 10, 2012
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
January 29, 2010
Date of Patent:
April 10, 2012
Assignees:
Genomic Health, Inc., NSABP Foundations, Inc.
Inventors:
Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett, Drew Watson, Soonmyung Paik
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
April 10, 2012
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Type:
Grant
Filed:
June 1, 2011
Date of Patent:
April 3, 2012
Assignee:
Genomic Health, Inc.
Inventors:
Joffre B. Baker, Maureen T. Cronin, Steven Shak, Jose Baselga
Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
December 6, 2011
Assignee:
Genomic Health, Inc.
Inventors:
Joffre B. Baker, Maureen T. Cronin, Michael C. Kiefer, Steve Shak, Michael Graham Walker
Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.
Type:
Grant
Filed:
March 13, 2009
Date of Patent:
November 29, 2011
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, Wayne Cowens, Kim Langone, James Hackett, Drew Watson, Soonmyung Paik
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
October 4, 2011
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
September 27, 2011
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Type:
Grant
Filed:
November 14, 2003
Date of Patent:
August 30, 2011
Assignee:
Genomic Health, Inc.
Inventors:
Joffre B. Baker, Maureen T. Cronin, Steve Shak, Jose Baselga
Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
Type:
Grant
Filed:
March 18, 2009
Date of Patent:
May 10, 2011
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
Type:
Grant
Filed:
November 4, 2005
Date of Patent:
April 19, 2011
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak